Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5638995 | 0.98 | MAOA (0.50) | MAOAMAOBADRB2ALDH1A1HTT | |
| SCHEMBL6672637 | 0.93 | MAOA (0.50) | MAOAMAOBHTTOPRM1OPRK1 | |
| SCHEMBL2374698 | 0.89 | MAOA (0.54) | MAOAMAOBHTTOPRM1OPRK1 | |
| SCHEMBL268688 | 0.77 | MAOA (0.52) | MAOAMAOBADRB2ALDH1A1HTT | |
| SCHEMBL4581280 | 0.77 | MAOA (0.52) | MAOAMAOBADRB2ALDH1A1HTT | |
| SCHEMBL1588016 | 0.77 | MAOA (0.52) | MAOAMAOBADRB2ALDH1A1HTT | |
| SCHEMBL8767085 | 0.77 | MAOA (0.47) | MAOAMAOBADRB2ALDH1A1HTT | |
| SCHEMBL8347115 | 0.75 | MAOA (0.54) | MAOAMAOBADRB2ALDH1A1HTT | |
| SCHEMBL17529707 | 0.74 | MAOA (0.48) | MAOAMAOBADRB2ALDH1A1HTT | |
| SCHEMBL22798325 | 0.74 | MAOA (0.48) | MAOAMAOBADRB2ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054819-A1 | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-03-10 | — | — | US | claimed |
| EP-1465862-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | SmithKline Beecham Corporation (US) | 2004-10-13 | — | — | EP | claimed |
| WO-2003062192-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-31 | — | — | WO | claimed |
| EP-1465862-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | SmithKline Beecham Corporation (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003062192-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054819-A1 | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors | CTSK, CTSS, CTSE | MAOA 2083/4885MAOB 2350/4885ADRB2 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.